Company
Corimmun GmbH is a private biotechnology company located in Martinsried near Munich, Germany. Corimmun was founded in 2006 as a spin-off from the Universities Würzburg and Tübingen. A seed financing was obtained from Hightech-Gründerfonds, Bayernkapital and Bio-M. in 2008, a series A financing was secured from MIG Fonds AG together with the ERP-Startfonds of the KFW-Bank and Bayernkapital.
Corimmun is a drug-developing company which focuses on inflammatory mechanisms in heart failure and atherosclerosis. We have constant scientific support from the outstanding university groups of our founders. The current projects are funded by two grants from the Go-Bio program of the national ministry of science and education (BMBF)